Stryker has announced it has received FDA clearance for new clot removal technology, according to a news release (pdf).
The Trevo Pro clot retriever is the latest in the company's Trevo line of products, and uses Stentriever technology for clot integration and retrieval in patients experiencing acute ischemic stroke, according to the company.
"The launch of this device is another great stride in the evolution of stroke care," said TREVO 2 Investigator Gary Duckwiler, MD, at the University of California Los Angeles Medical Center, in the release. "Concentric Medical, which is now owned by Stryker, has a long history of partnering with physicians to develop devices specifically designed to remove blood clots from a blocked artery in the brain. The new Trevo Pro retriever is easy to use and very effective at opening blood vessels; allowing physicians to have a significant impact on clinical outcomes."
Stryker is headquartered in Kalamazoo, Mich.
Related Articles on FDA Clearances:
GeNO Receives FDA Clearance for Inhaled Nitric Oxide Drug Delivery Device
Philips and Celsion Receive FDA Clearance for Phase II Study of Bone Cancer Device
Codman Receives FDA Clearance for Programmable Infusion System